Technological Advances in Glucose Management in Older Adults

Completed · Not applicable

Conditions studied: Type 1 Diabetes Mellitus, Older Adults, Hypoglycemia

In brief

This is a study to assess the effectiveness of CGM (Continuous Glucose Monitor), enhanced by a diabetes management platform (DMP), collectively called enhanced CGM (eCGM), in the care of older patients with T1D. The DMP includes an automated data transfer from CGM, insulin-delivery devices, and activity tracker to a clinical decision support system (CDS) that provides dosing adjustment recommendations based on that data to the healthcare team. In addition, the DMP includes on-demand education for patients and caregivers, and an interface for communication between providers, patients, and their caregivers.

Key facts

Study ID

NCT03078491

Run by

Joslin Diabetes Center

People needed

168

Starts

2017-03-30

Expected to finish

2022-10-01

Last updated by the study team

2026-05-12

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with age ≥ 65 years
• Community-living
• Clinical diagnosis of T1D
• On multiple insulin injections (≥3 injection/s day) or insulin pump.

You may not qualify if…

• Use of real-time CGM in past 2 years
• A1c > 10% (since individuals with very poor glycemic control usually have barriers to optimal self-care that preclude effective use of technology)
• Use of insulin pump that cannot be uploaded for CDS
• Unable or unwilling to perform task needed for study participation during the run-in period
• Severe vision or hearing impairment that could interfere with study tasks
• Need to use acetaminophen on regular basis (since can interfere with CGM accuracy)
• Living in an institutional setting (e.g. group homes, nursing homes)
• Terminal diseases with life expectancy < 1 year (e.g. malignancy)
• Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)
• Alcohol or other drug abuse
• Conditions that impact wear of CGM (e.g. CHF with edema, skin conditions); and
• End stage renal insufficiency (eGFR<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood).

Where it is running

• Joslin Diabetes Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.